www.the-scientist.com

Share

www.the-scientist.com

 •  November 24

An analysis of President Trump’s proposed $7.2 billion slash to the National Institutes of Health budget points to dire consequences for the development of novel drugs. In March, President Donald Trump’s administration released its proposed 2018 budget, which included a significant cut to funding for the National Institutes of Health (NIH). Now, an...

www.the-scientist.com

 •  April 17

A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? When researchers at Cold Spring Harbor Laboratory set out to confirm cancer cells’ dependence on MELK, a gene coding for a protein kinase shown by countless RNA interference...

www.the-scientist.com

 •  March 1

What can be done to lower development costs and drug prices? Drug approvals by the US Food and Drug Administration (FDA) dropped dramatically in 2016—down by 57 percent over the year before. While some of this decline was due to a record number of approvals in 2015, only 22 novel drugs were approved last year—fewer than in each of the previous five...

www.the-scientist.com

 •  February 14

Using patients’ own immune systems to fight cancer More than a century ago, American bone surgeon William Coley came across the case of Fred Stein, whose aggressive cheek sarcoma had disappeared after he suffered a Streptococcus pyogenes infection following surgery to remove part of the large tumor. Seven years later, Coley tracked Stein down and...